GENEREX BIOTECHNOLOGY CORP (GNBT) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 55 transactions totaling $782.7K, demonstrating a bearish sentiment with -$124.2K in net insider flow. The most recent transaction on Nov 16, 2019 involved a purchase of 10,000 shares valued at $5.1K.
No significant insider buying has been recorded for GNBT in the recent period.
No significant insider selling has been recorded for GNBT in the recent period.
Based on recent SEC filings, insider sentiment for GNBT is bearish with an Insider Alignment Score of 42/100 and a net flow of -$124.2K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at GENEREX BIOTECHNOLOGY CORP (GNBT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading GNBT stock, having executed 55 transactions in the past 90 days. The most active insider is Mark Fletcher (Executive), who has made 14 transactions totaling $513.1K.
Get notified when executives and directors at GNBT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 16, 2019 | E. Gluskin Anna | Executive | Purchase | 10,000 | $0.51 | $5.1K | |
| Dec 7, 2018 | Gray Haines Harold | Executive | Purchase | 300 | $1.03 | $309 | |
| Dec 7, 2018 | Gray Haines Harold | Executive | Purchase | 8,000 | $1.05 | $8.4K | |
| Dec 4, 2018 | Gray Haines Harold | Executive | Purchase | 945 | $2.12 | $2.0K | |
| Dec 4, 2018 | Gray Haines Harold | Executive | Purchase | 555 | $2.10 | $1.2K | |
| Feb 16, 2016 | Fletcher Mark | Executive | Option Exercise | 4,447,111 | $N/A | $0 | |
| Feb 16, 2016 | Brusegard David | Executive | Option Exercise | 1,667,671 | $N/A | $0 | |
| Feb 9, 2016 | Fletcher Mark | Executive | Option Exercise | 14,890,033 | $N/A | $0 | |
| Feb 9, 2016 | Brusegard David | Executive | Option Exercise | 5,583,775 | $N/A | $0 | |
| Apr 27, 2015 | P. Barratt John | Executive | Option Exercise | 5,874,162 | $N/A | $0 | |
| Oct 6, 2014 | Mcgee Brian | Executive | Option Exercise | 35,714 | $N/A | $0 | |
| Oct 6, 2014 | P. Barratt John | Executive | Option Exercise | 35,714 | $N/A | $0 | |
| Oct 6, 2014 | Fletcher Mark | Executive | Option Exercise | 470,726 | $N/A | $0 | |
| Jun 18, 2013 | Fellows Stephen | Executive | Sale | 2,524,164 | $0.04 | $101.0K | |
| Jun 6, 2013 | Fellows Stephen | Executive | Option Exercise | 2,524,164 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 9 | $453.4K | 39.9% |
Exercise(M) | 15 | $342.5K | 30.1% |
Purchase(P) | 22 | $329.3K | 29.0% |
Award(A) | 9 | $12.1K | 1.1% |
Insider activity at GENEREX BIOTECHNOLOGY CORP shows mixed signals across all time. While $329.3K in purchases indicates some executive confidence,$453.4K in sales balances the picture, resulting in a modest net flow of -$124.2K.12 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Mark Fletcher, has transacted $513.1K during this period.